Mammary Cell News Volume 13.19 | May 20, 2021

    0
    77







    2021-05-20 | MCN 13.19


    Mammary Cell News by STEMCELL Technologies
    Vol. 13.19 – 20 May, 2021
    TOP STORY

    A Prometastatic Splicing Program Regulated by SNRPA1 Interactions with Structured RNA Elements

    Researchers established a noncanonical function for small nuclear ribonucleoprotein polypeptide A′ (SNRPA1) and a previously unknown RNA structural code that regulated alternative splicing, and found that this SNRPA1-mediated pathway acted as a promoter of breast cancer metastasis.
    [Science]

    AbstractPress Release

    Guide to everything you need to know about cell separation.
    PUBLICATIONSRanked by the impact factor of the journal

    Repression of Endogenous Retroviruses Prevents Antiviral Immune Response and Is Required for Mammary Gland Development

    Investigators demonstrated that the loss of the lysine 9 of histone H3 methyltransferase G9a in the mammary epithelium resulted in de novo chromatin opening, aberrant formation of the mammary ductal tree, impaired stem cell potential, disrupted intraductal polarity, and loss of tissue function.
    [Cell Stem Cell]

    AbstractGraphical Abstract

    BAD Regulates Mammary Gland Morphogenesis by 4E-BP1-Mediated Control of Localized Translation in Mouse and Human Models

    Researchers described a role for the Bcl-2 family member BAD in postnatal mammary gland morphogenesis that involves controlling localized translation and cell migration during gland development.
    [Nature Communications]

    Full Article

    Mismatch Repair Deficiency Predicts Response to HER2 Blockade in HER2-Negative Breast Cancer

    The authors suggested MutL loss as a predictive marker of sensitivity to combinatorial treatment with endocrine intervention and HER inhibitors in endocrine treatment-resistant ER+/HER2 breast cancer patients.
    [Nature Communications]

    Full ArticlePress Release

    RANK Links Senescence to Stemness in the Mammary Epithelia, Delaying Tumor Onset but Increasing Tumor Aggressiveness

    Investigators uncovered a dual role for Rank in the mammary epithelia: Rank induced senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness.
    [Developmental Cell]

    Full ArticleGraphical Abstract

    Cell Lineage Tracing Links ERα Loss in Erbb2-Positive Breast Cancers to the Arising of a Highly Aggressive Breast Cancer Subtype

    Scientists generated mice that produced an RFP-marked ERα+ mammary gland epithelial cell lineage to investigate ERα dependencies and their implications during breast cancer growth and metastasis.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    Metastasis-Suppressor NME1 Controls the Invasive Switch of Breast Cancer by Regulating MT1-MMP Surface Clearance

    The authors investigated the contribution of nucleoside diphosphate kinase (NME1), a known metastasis suppressor, to local invasion in breast cancer.
    [Oncogene]

    Full Article

    USP22 Promotes HER2-Driven Mammary Carcinoma Aggressiveness by Suppressing the Unfolded Protein Response

    Scientists investigated the role of Ubiquitin-Specific Protease 22 (USP22) in HER2-driven breast cancer (HER2+-BC) and demonstrated that USP22 was required for the tumorigenic properties in murine and human HER2+-BC models.
    [Oncogene]

    Full Article

    Notch3 Inhibits Cell Proliferation and Tumorigenesis and Predicts Better Prognosis in Breast Cancer through Transactivating PTEN

    Investigators studied the interaction between Notch receptors (Notch1-4) and PTEN, and demonstrated that Notch3 inhibited breast cancer proliferation and suppressed tumorigenesis by transactivating PTEN expression.
    [Cell Death & Disease]

    Full Article

    Let-7f miRNA Regulates SDF-1α- and Hypoxia-Promoted Migration of Mesenchymal Stem Cells and Attenuates Mammary Tumor Growth upon Exosomal Release

    The authors examined intracellular levels of let-7f in 4T1 mammary carcinoma cells to test the hypothesis that let-7f released from human mesenchymal stem cells may be incorporated by tumor cells.
    [Cell Death & Disease]

    Full Article

    Bispecific Antibody Simultaneously Targeting PD1 and HER2 Inhibits Tumor Growth via Direct Tumor Cell Killing in Combination with PD1/PDL1 Blockade and HER2 Inhibition

    Scientists developed a bispecific antibody simultaneously targeting both PD1 and HER2 in an attempt to combine HER2-targeted therapy with immune checkpoint blockade for treating HER2-positive solid tumors.
    [Acta Pharmacologica Sinica]

    Full Article

    CD133 mRNA Transfected Dendritic Cells Induces a Coordinated Cytotoxic and Helper T Cell Responses against Breast Cancer Stem Cells.

    Researchers hypothesized that by creating an MHC independent vaccination, they would give rise to a sustained immune response against CD133 in triple negative breast carcinomas.
    [Molecular Therapy-Oncolytics]

    AbstractFull ArticleGraphical Abstract

    Regeneration Linked miRNA Modify Tumor Phenotype and Can Enforce Multi-Lineage Growth Arrest In Vivo

    Scientists showed that inhibition of miRNAs – 503 and – 23a, alone or in combination, enhanced tumor proliferation in vitro.
    [Scientific Reports]

    Full Article
    Register for a recorded organoid panel discussion moderated by Dr. James Wells
    REVIEWS

    Nuclear Localisation of Aurora-A: Its Regulation and Significance for Aurora-A Functions in Cancer

    The authors examine potential links between Aurora-A stabilisation and localisation, and discuss them in the perspective of a more effective targeting of Aurora-A in cancer therapy.
    [Oncogene]

    Full Article

    Protein Arginine Methyltransferases: Promising Targets for Cancer Therapy

    Researchers discuss the biological functions of protein arginine methyltransferases (PRMTs) in cancer and the current development status of PRMT inhibitors in cancer therapy.
    [Experimental & Molecular Medicine]

    Full Article

    INDUSTRY AND POLICY NEWS

    Dana-Farber Announces Expanded Joint Research Agreement with Novartis

    Novartis is continuing to support Dana-Farber Cancer Institute’s development of transformative medicines to address current and future needs in cancer care, including research on TNBC resistance to CDK4/6 inhibitors.
    [Dana-Farber Cancer Institute]

    Press Release

    FEATURED EVENT

    8th International Conference on Stem Cell Engineering 2021

    July 8 – 10, 2021
    Boston, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Associate – Primary Human Tumors

    Louisiana State University – New Orleans, Louisiana, United States

    Postdoctoral Associate – Breast Cancer Hormone Therapy Resistance

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Fellow – Translational Breast Cancer Research

    University of Texas Southwestern Medical Center – Dallas, Texas, United States

    Scientist – Stromal Biology

    Bristol Myers Squibb – Redwood City, California, United States

    Postdoctoral Fellowships – Clinical Cancer Prevention

    The University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter